(Q47290558)

English

ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL. (English)

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

Paul E Sax

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

author name string

Babafemi O Taiwo

1

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Lu Zheng

2

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Andrei Stefanescu

3

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Amesika Nyaku

4

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Baiba Bezins

5

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Carole L Wallis

6

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Catherine Godfrey

7

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Edward Acosta

9

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

David Haas

10

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Kimberly Y Smith

11

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Beverly Sha

12

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Cornelius Van Dam

13

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Roy M Gulick

14

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

language of work or name

0 references

publication date

14 December 2017

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Clinical Infectious Diseases

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Emergent drug resistance with integrase strand transfer inhibitor-based regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Primary resistance to integrase strand-transfer inhibitors in Europe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

2014 Update of the drug resistance mutations in HIV-1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the ran

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5961075

26 August 2018

Identifiers

10.1093/CID/CIX1083

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

release_orxewpj3cvghrcnnrp6kzl3f7u

1 reference

https://api.fatcat.wiki/v0/release/orxewpj3cvghrcnnrp6kzl3f7u

24 November 2022

based on heuristic

mapped directly with Wikidata item

0 references

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/29253097

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47290558&oldid=1843276102"